GRI Bio, Inc. (NasdaqCM: GRI)
Health Care · Biotechnology · US
$1.38
-20.69% today · -97.6% 1Y
GRI Bio, Inc. (NasdaqCM: GRI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.02M and employs 4 people.
Over the last twelve months the share price has lost 97.6%, trading between 1.36 and 64.12.
Tweenvest scores GRI Bio, Inc. across four factors: quality 35/100, value 24/100. Its strongest factor is quality.
GRI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.02M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -11.55
- Dividend yield
- —
- Beta (5Y)
- -0.61
- 52-week high
- $64.12
- 52-week low
- $1.36
- Avg volume (3M)
- —
- Shares outstanding
- 2.19M
- Employees
- 4
- Next earnings
- —
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
- ISIN
- US3622AW5029
- Founded
- 2009
- Listed since
- Feb 10, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Chosa Oncology ABNGM: CHOSA | $3.31M | Skr— | — |
| Affymax, Inc.OTCPK: AFFY | $3.10M | $0.04 | +2500.00% |
| Calidi Biotherapeutics, Inc.NYSEAM: CLDI | $3.09M | $0.84 | -18.74% |
| Restart Life Sciences Corp.CNSX: HEAL | $3.06M | CA$0.07 | -6.67% |
| Eocene Ltd.NasdaqCM: EOCN | $2.97M | $2.85 | -19.49% |
| Aptevo Therapeutics Inc.NasdaqCM: APVO | $2.92M | $1.62 | -9.50% |
| Mustang Bio, Inc.NasdaqCM: MBIO | $2.85M | $0.38 | -5.92% |
| BSF Enterprise PlcLSE: BSFA | $2.82M | £0.01 | +0.00% |
Figures last refreshed Oct 18, 2026.